Frequently Asked Questions
The global POC molecular diagnostics market was valued at USD 6.9 Billion in 2022.
The POC molecular diagnostics market is expected to grow at a CAGR of 3.3% between 2023 and 2030, reaching USD 8.6 Billion in 2030.
PCR-based is the leading segment by technology, holding over 30% share in value in 2022.
Infectious diseases govern the global demand for POC molecular diagnostics, holding a massive share of over 50% in 2022.
The POC segment is expected to post the highest CAGR during the forecast period.
North America is fueling the growth of the POC molecular diagnostics industry, with an over one-third share in 2022.
The top players include Abbott, Bayer AG, F. Hoffmann-La Roche AG, Nova Biomedical, and QIAGEN.
The major market drivers are increasing demand for rapid and accurate diagnostic testing, rising prevalence of infectious diseases, advancements in digital health technologies, and growing need for early detection and personalized medicine.
The major market restraints include a complex regulatory landscape, stringent quality standards, and high cost associated with developing and implementing POC molecular diagnostics.
Expansion into emerging markets with growing healthcare infrastructure, integration of POC molecular diagnostics with digital health technologies, and development of cost-effective and user-friendly POC molecular diagnostic solutions.